CLDX
- Celldex Therapeutics, Inc.
()
Overview
Company Summary
Celldex Therapeutics, Inc. is a biotechnology company dedicated to the development and commercialization of innovative immunotherapies for the treatment of various diseases, primarily cancer. Founded in 1983, Celldex focuses on harnessing the power of the immune system to combat cancer cells.
The company's primary focus is on developing targeted antibody-based therapies and immune system modulators. These therapies work by stimulating the body's immune response to identify and attack cancer cells specifically, while minimizing damage to healthy cells.
Celldex has built a comprehensive pipeline of potential drugs, with each drug designed to target different types of cancer or specific patient populations. These experimental drugs are currently being tested in clinical trials to assess their safety and efficacy.
One of their most promising drug candidates is glembatumumab vedotin (glemba), which is being evaluated for the treatment of breast, squamous cell lung, and other types of cancer. Another notable drug candidate is varlilumab, an immune system modulator that is being tested in combination with other immunotherapies.
Celldex also pioneered the development of antibody-drug conjugates (ADCs), which are designed to deliver potent cytotoxic drugs directly to cancer cells. Their lead ADC candidate, CDX-0159, is being developed for the treatment of rare mast cell-related diseases.
In addition to its product development efforts, Celldex actively collaborates with academic institutions, government agencies, and other biopharmaceutical companies to advance its research and expand its portfolio.
Overall, Celldex Therapeutics is committed to revolutionizing cancer treatment through the development of innovative immunotherapies that have the potential to improve patient outcomes and quality of life.